Panel seeks 20% cap on drug, medical device mark-ups | India News


Panel seeks 20% cap on drug, medical device mark-ups
A parliamentary panel said the gap between landing cost and MRP needs to be reduced to make medicines and medical devices more affordable. (Representative Image)

NEW DELHI: A parliamentary panel has recommended that the gap between the landing price, or the cost at which a medicine or medical device reaches the market, and its MRP should not exceed 20%, citing wide price disparities that can increase patients’ out-of-pocket expenditure.The Standing Committee on Health and Family Welfare cited Tenecteplase, a life-saving clot-busting drug used during the golden hour of a heart attack, as an example. According to the report, its landing cost is Rs 18,000, while the MRP is Rs 50,000, with patients being billed at the MRP.The panel said the gap between landing cost and MRP needs to be reduced to make medicines and medical devices more affordable. It also recommended rationalising the prices of peripheral stents and drug-eluting balloons.Pointing to the impact of price regulation, the committee noted that cardiac stents, which earlier cost around Rs 1.9 lakh, were capped at Rs 25,000-30,000 in 2017.The panel, however, stressed that lowering prices should not compromise the quality or availability of medical devices. It recommended strict quality-management systems for manufacturers and called for measures to prevent shortages and black marketing while rationalising prices of high-end medical consumables.

Share your thoughts in the comments